Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,012 stories, page 719 of 767

Advanced search

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma to Present at Upcoming Investor Conferences in June - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma to Present at BIO CEO Investor Conference - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma Secures $20.5 Million in Series B Financing - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma Announces Publication of Positive Alzheimer's Disease Clinical Study Data with Neflamapimod - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma announces presentation of new mechanism of action data regarding neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC) - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma announces presentation of new positive clinical data with neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC) - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor - CervoMed

CervoMedOriginal source

🌍Jun 27, 2019Industrycervomed.comTier 1 · Company source

EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) - CervoMed

CervoMedOriginal source

🇺🇸Jun 26, 2019CROflorencehc.comTier 2 · Direct publisher

Technology in Multicenter Clinical Trials

Florence HealthcareOriginal source

🌍Jun 21, 2019Industryemzorpharma.comTier 1 · Company source

AFCON 2019 Kicks Off Today!

Emzor PharmaceuticalOriginal source

🌍Jun 12, 2019Industryir.cyclerion.comTier 1 · Company source

Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP

Cyclerion TherapeuticsOriginal source

🌍Jun 6, 2019Industryemzorpharma.comTier 1 · Company source

Dr Stella Okoli, CEO Emzor Pharmaceutical to be Inducted into Nigerian Women Hall of Fame by Federal Government

Emzor PharmaceuticalOriginal source

🌍Jun 5, 2019Industryir.cyclerion.comTier 1 · Company source

Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings

Cyclerion TherapeuticsOriginal source

🌍May 22, 2019Industryemzorpharma.comTier 1 · Company source

Emzor Para 1000 Features in Music Video, Ringi Ringi by Akuchi Ft. Olamide

Emzor PharmaceuticalOriginal source

🇩🇰May 16, 2019Industryserviersymphogen.comTier 3 · Secondary coverage

Symphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials

SymphogenOriginal source

🇩🇰May 15, 2019Industryserviersymphogen.comTier 3 · Secondary coverage

Symphogen announces new capital raise and explores strategic options

SymphogenOriginal source

🌍May 13, 2019Industryir.cyclerion.comTier 1 · Company source

Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company

Cyclerion TherapeuticsOriginal source

🌍Apr 25, 2019Industryir.cyclerion.comTier 1 · Company source

Cyclerion to Host Corporate Overview Call on May 13, 2019

Cyclerion TherapeuticsOriginal source

🇺🇸Apr 23, 2019CROflorencehc.comTier 2 · Direct publisher

FDA: Technology’s Value in a World of Precision Medicine and Research

Florence HealthcareOriginal source

🌍Apr 9, 2019Industryir.cyclerion.comTier 1 · Company source

Cyclerion Announces the Appointment of Andreas Busch, Ph.D., as Chief Innovation Officer

Cyclerion TherapeuticsOriginal source

🌍Apr 2, 2019Industryir.cyclerion.comTier 1 · Company source

Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases

Cyclerion TherapeuticsOriginal source

🇺🇸Mar 28, 2019CROflorencehc.comTier 2 · Direct publisher

ALCOA-C in Clinical Trial Electronic Document Management

Florence HealthcareOriginal source

🇺🇸Mar 19, 2019Researchcidrap.umn.eduTier 2 · Direct publisher

Stewardship / Resistance Scan for Mar 18, 2019

CIDRAPOriginal source

🌍Mar 14, 2019Industryemzorpharma.comTier 1 · Company source

Emzor’s Position on the BBC Documentary on Codeine

Emzor PharmaceuticalOriginal source

🇺🇸Mar 14, 2019Researchcidrap.umn.eduTier 2 · Direct publisher

Antibiotics before miscarriage surgery not tied to fewer infections

CIDRAPOriginal source

🌍Feb 27, 2019Industryir.cyclerion.comTier 1 · Company source

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

Cyclerion TherapeuticsOriginal source

🇺🇸Feb 13, 2019CROflorencehc.comTier 2 · Direct publisher

5 Key Advantages of eRegulatory

Florence HealthcareOriginal source

🇺🇸Jan 30, 2019CROflorencehc.comTier 2 · Direct publisher

Observations from TMF Summit 2019: The Post-eTMF World

Florence HealthcareOriginal source

🌍Jan 29, 2019Industryir.cyclerion.comTier 1 · Company source

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

Cyclerion TherapeuticsOriginal source

🇺🇸Jan 19, 2019CROflorencehc.comTier 2 · Direct publisher

How Lauren Begnaud Transitioned 65 Sites to eRegulatory at US Oncology

Florence HealthcareOriginal source

🇺🇸Dec 29, 2018CROflorencehc.comTier 2 · Direct publisher

Thank you for a great 2018!

Florence HealthcareOriginal source

🇺🇸Dec 20, 2018CROflorencehc.comTier 2 · Direct publisher

Key Expectations of Clinical Trial Operations Leaders in 2019

Florence HealthcareOriginal source

🇺🇸Oct 25, 2018CROflorencehc.comTier 2 · Direct publisher

Four Observations from Site Solutions Summit

Florence HealthcareOriginal source

🇺🇸Sep 13, 2018CROflorencehc.comTier 2 · Direct publisher

Ten Ways Florence eBinders™ Accelerates Study Startup

Florence HealthcareOriginal source

🇺🇸Sep 11, 2018CROflorencehc.comTier 2 · Direct publisher

Florence Named to Top 100 Places to Work in Atlanta

Florence HealthcareOriginal source

🇩🇰Sep 3, 2018Industryserviersymphogen.comTier 3 · Secondary coverage

Symphogen elects new Board members to support the Company’s long-term development

SymphogenOriginal source

🇺🇸Aug 18, 2018CROflorencehc.comTier 2 · Direct publisher

4 Strategies for ICH GCP E6(R2) Compliance

Florence HealthcareOriginal source

🇺🇸Aug 13, 2018CROflorencehc.comTier 2 · Direct publisher

Guide | FDA Inspections of Trial Sites with Electronic Systems

Florence HealthcareOriginal source

🇺🇸Aug 7, 2018CROflorencehc.comTier 2 · Direct publisher

Ten Must-Have Capabilities When Evaluating eRegulatory Platforms

Florence HealthcareOriginal source

🇬🇧Jun 26, 2018Researchhdruk.ac.ukTier 2 · Direct publisher

Rhos Walker becomes Chief Strategy Officer at HDR UK

Health Data Research UKOriginal source

🇩🇰May 30, 2018Industryserviersymphogen.comTier 3 · Secondary coverage

Symphogen further strengthens its immuno-oncology pipeline by advancing into two additional clinical trials

SymphogenOriginal source

🇺🇸Mar 20, 2018Researchcidrap.umn.eduTier 2 · Direct publisher

Study: Non-antibiotic drugs affect gut bacteria, could promote resistance

CIDRAPOriginal source

🇪🇬Jan 21, 2018Industrydeltapharma.comTier 1 · Company source

Ferias internacionales 2025

Delta PharmaOriginal source

🇩🇰Nov 30, 2017Industryserviersymphogen.comTier 3 · Secondary coverage

Symphogen receives milestone payment for initiation of Phase 1b trial in infectious disease

SymphogenOriginal source

🇩🇰Sep 11, 2017Industryserviersymphogen.comTier 3 · Secondary coverage

Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

SymphogenOriginal source

🇩🇰Aug 31, 2017Industryserviersymphogen.comTier 3 · Secondary coverage

Symphogen presents Sym004 Phase 2 data at ESMO 2017 Congress

SymphogenOriginal source

🇪🇬Jul 18, 2017Industrydeltapharma.comTier 1 · Company source

¡UNA NUEVA UBICACIÓN!

Delta PharmaOriginal source

🌍Jul 16, 2017Industryimmutep.comTier 1 · Company source

Prima BioMed Announces Second Milestone Payment for IMP701 Program - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jul 9, 2017Industryimmutep.comTier 1 · Company source

Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jun 29, 2017Industryimmutep.comTier 1 · Company source

Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jun 26, 2017Industryimmutep.comTier 1 · Company source

Operational Update - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jun 6, 2017Industryimmutep.comTier 1 · Company source

ASCO Poster 2017 - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍Jun 4, 2017Industryimmutep.comTier 1 · Company source

LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍May 31, 2017Industryimmutep.comTier 1 · Company source

Prima BioMed Announces Formation of Clinical Advisory Board - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source

🌍May 17, 2017Industryimmutep.comTier 1 · Company source

Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference - Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

ImmutepOriginal source